Knowledge graph · Cancer
Neoplasm of Uncertain Histogenesis
cancer
- Identifier
- CI-CAN-00000034
- Entity page
- /cancer/neoplasm-of-uncertain-histogenesis ↗
- Edges
- 15,704
- Neighbours
- 15 genes57 drugs10 trials
- Drawn
- 60 of 82 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Neoplasm of Uncertain Histogenesis approved for …APPROVED_FORderived96 of 96show fewer | ||||||||
| ← approved for | Sevabertinibsmall molecule FDA (US) · approved · 2025-11-19 · HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)… | — | approved | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Regulatory | openfda | graph → |